ASH 2017 | Advancements in AML therapy at ASH 2017
Amir Fathi
• 9 Dec 2017
Over the past 10 years, there has been a massive expansion in the number and classes of treatments available for myeloid malignancies. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Dr Amir Fathi, MD, of the Dana-Farber Cancer Institute, Boston, MA, provides insight into the exciting areas of advancement in acute myeloid leukaemia (AML). He highlights clinical trials evaluating IDH and FLT3 inhibitors, antibody-drug conjugates, and liposomal formulations of traditional chemotherapeutic drugs, all of which have demonstrated various extents of clinical promise.
